title: Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer.
abstract: BACKGROUND
  This study was designed to determine the recommended dose of carboplatin-pemetrexed in elderly (≥75 years old), chemotherapy-naive patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC).
  
  
  METHODS
  Patients received escalated doses of carboplatin and pemetrexed every 3 weeks for four cycles. Patients with an objective response and stable disease continued pemetrexed therapy until disease progression or unacceptable toxicity was observed.
  
  
  RESULTS
  The combination of carboplatin at an area under the concentration-time curve (AUC) of 5, and 500 mg/m(2) pemetrexed, was determined to be the recommended dose for elderly patients with advanced nonsquamous NSCLC. Of 17 patients, 10 received a median of five cycles of pemetrexed maintenance therapy without unexpected or cumulative toxic effects. The study had an overall response rate of 47.1%. The median progression-free survival time was 142 days (95% confidence interval [CI] 68-216 days) and the median overall survival time was 461 days (95% CI 168-754 days).
  
  
  CONCLUSIONS
  This combination was a tolerable and effective regimen, and recommended dose (RD) was carboplatin [area under the curve (AUC) of 5]/pemetrexed (500 mg/m(2)) every 3 weeks, in chemotherapy-naïve, elderly (≥75 years old) patients with advanced nonsquamous NSCLC.
authors.affiliation: Department of Internal Medicine, Kinki-Chuo Chest Medical Center, Osaka, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Tamiya
authors.forename: M
authors.initials: M
authors.lastname: Tamiya
authors.forename: T
authors.initials: T
authors.lastname: Shiroyama
authors.forename: M
authors.initials: M
authors.lastname: Kanazu
authors.forename: A
authors.initials: A
authors.lastname: Hirooka
authors.forename: T
authors.initials: T
authors.lastname: Tsuji
authors.forename: N
authors.initials: N
authors.lastname: Morishita
authors.forename: K
authors.initials: K
authors.lastname: Asami
authors.forename: H
authors.initials: H
authors.lastname: Suzuki
authors.forename: N
authors.initials: N
authors.lastname: Okamoto
authors.forename: K
authors.initials: K
authors.lastname: Okishio
authors.forename: T
authors.initials: T
authors.lastname: Kawaguchi
authors.forename: T
authors.initials: T
authors.lastname: Hirashima
authors.forename: S
authors.initials: S
authors.lastname: Atagi
authors.forename: I
authors.initials: I
authors.lastname: Kawase
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D019540:Area Under Curve; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005971:Glutamates / Q000008:administration & dosage* / Q000009:adverse effects; D006147:Guanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D000068437:Pemetrexed; D015996:Survival Rate
chemical_list: D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine; D016190:Carboplatin